Tumor Debulking in Combination With Chemotherapy in Multiorgan Metastatic Colorectal Cancer: The ORCHESTRA Randomized Clinical Trial

Gastrointestinal Cancer

First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAF(V600E)-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group)

Eur J Cancer

Weiss L, Stintzing S, Modest DP, Stahler A, von Weikersthal LF, Reinacher-Schick A, Decker T, Probst V, Heinrich K, Schwaner I, Kaiser F, Pihusch R, Fuchs M, Held S, Alig A, Gruenberger B, Prager GW, Tougeron D, Taieb J, Heinemann V

doi: 10.1016/j.ejca.2025.116105

Gastrointestinal Cancer

Dynamic Circulating Tumor DNA Methylation Monitoring Guiding Postoperative Surveillance in Nonmetastatic Colorectal Cancer: A Prospective, Randomized, Phase III FIND Trial

J Clin Oncol

Mo S, Zhou C, Ma M, Luo W, Li Y, Lu P, Tang P, Li Y, Ma X, Hu X, Cheng C, Yang J, Zhuo C, Jian J, Yu C, Ding J, Xiong C, Jiang F, Mu R, Lu Z, Yu J, Jin S, Luan J, Li X, Cai S, Zou H, Li Y, Li Q, Liu F, Ding C, Peng J

doi: 10.1200/JCO-25-03009

Gastrointestinal Cancer

Time-dependent recurrence patterns after curative resection for stage II/III colorectal cancer: An integrated analysis of four phase III randomized controlled trials (JCOG2310A-S4)

Eur J Cancer

Tashiro K, Osumi H, Kataoka K, Shimada Y, Inomata M, Hamaguchi T, Takii Y, Suwa Y, Mizusawa J, Sano Y, Suto T, Murata K, Adachi T, Ueno H, Ikeda S, Komori K, Shiozawa M, Tsukamoto S, Takashima A, Kanemitsu Y

doi: 10.1016/j.ejca.2026.116957

Gastrointestinal Cancer

Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up

Adv Ther

Cruz-Correa M, Oh DY, Kato K, Tabernero J, Bai Y, Shi J, Lee KW, Hirano H, Spigel D, Wyrwicz L, Pazo Cid R, Cubillo Gracián A, Xu Y, Sheng T, Yang S, Xu RH, Moehler M

doi: 10.1007/s12325-025-03415-0

Gastrointestinal Cancer

Clinical outcomes of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil or regorafenib in metastatic colorectal cancer: a multicenter cohort study

ESMO Open

Moik F, Huemer F, Doleschal B, Taghizadeh H, Reimann P, Kostmann SM, Wagner L, Abdel Hamid M, Zimmer KC, Suppé SA, Bachleitner C, Schaberl-Moser R, Amann A, Wolf D, Greil R, Jost PJ, Winder T, Rumpold H, Weiss L, Gerger A, Seeber A, Riedl JM

doi: 10.1016/j.esmoop.2026.106907

Colonoscopy

The VISION-AI Trial: protocol for a pragmatic randomized controlled non-inferiority trial comparing artificial intelligence-guided colonoscopy to pancolonic chromoendoscopy for neoplasia detection in adults with colorectal inflammatory bowel disease

BMC Gastroenterol

Laforce-van Lierop LMA, Dang R, Narula N, Ingram RJM, Murthy SK, Hoentjen F

doi: 10.1186/s12876-026-05046-3

Further Publications

Heterogeneity of treatment preferences in the absence of guideline recommendations - a case vignette study in colorectal cancer tumor boards in Germany, Austria and Switzerland

BMC Gastroenterol

Soff J, Benz SR, Kowalski C, Hansinger J, Gerken M, Maier D, Kim-Wanner SZ, Witzmann J, Reinacher-Schick A, Pox CP, Kleihues-van Tol K, Franke B, Schoffer O, Schmitt J, Klinkhammer-Schalke M, Völkel V, onkoFDZ Study Group

doi: 10.1186/s12876-025-04183-5

Gastrointestinal Cancer

Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer

N Engl J Med

O'Reilly EM, Wainberg ZA, Hendifar AE, Borad MJ, Pietrantonio F, Pant S, Hammel P, Cremolini C, Manji GA, Oberstein PE, Garrido-Laguna I, Springfeld C, Azad NS, Ueno M, Chui SY, Zhang Y, Patel H, Lee Y, Salman Z, Wolpin BM, RASolute 302 Trial Investigators

doi: 10.1056/NEJMoa2605555

Gastrointestinal Cancer

Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial

Lancet

Hecht JR, Park YS, Tabernero J, Lee MA, Lee S, Virgili AC, Van den Eynde M, Fontana E, Fakih M, Asghari G, So J, Stein A, Dubreuil O, Bodnar L, He CS, Wang G, Smith R, Eng C, Saeed A, STELLAR-303 study investigators

doi: 10.1016/S0140-6736(25)02025-2

Related content

First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAF(V600E)-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group)

Dynamic Circulating Tumor DNA Methylation Monitoring Guiding Postoperative Surveillance in Nonmetastatic Colorectal Cancer: A Prospective, Randomized, Phase III FIND Trial

Time-dependent recurrence patterns after curative resection for stage II/III colorectal cancer: An integrated analysis of four phase III randomized controlled trials (JCOG2310A-S4)

Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up

Clinical outcomes of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil or regorafenib in metastatic colorectal cancer: a multicenter cohort study

The VISION-AI Trial: protocol for a pragmatic randomized controlled non-inferiority trial comparing artificial intelligence-guided colonoscopy to pancolonic chromoendoscopy for neoplasia detection in adults with colorectal inflammatory bowel disease

Heterogeneity of treatment preferences in the absence of guideline recommendations - a case vignette study in colorectal cancer tumor boards in Germany, Austria and Switzerland

Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer

Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial